Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Interest & Investment Income (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Interest & Investment Income data on record, last reported at $2.1 million in Q1 2025.

  • For Q1 2025, Interest & Investment Income fell 18.27% year-over-year to $2.1 million; the TTM value through Mar 2025 reached $10.1 million, up 43.07%, while the annual FY2025 figure was $8.7 million, 18.22% down from the prior year.
  • Interest & Investment Income reached $2.1 million in Q1 2025 per AMPH's latest filing, down from $2.3 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.3 million in Q2 2024 and bottomed at $141000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $1.2 million, with a median of $924000.0 recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: decreased 28.28% in 2021, then skyrocketed 410.5% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $157000.0 in 2021, then skyrocketed by 269.43% to $580000.0 in 2022, then soared by 297.07% to $2.3 million in 2023, then dropped by 0.48% to $2.3 million in 2024, then dropped by 8.86% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $2.1 million in Q1 2025, $2.3 million in Q4 2024, and $2.4 million in Q3 2024.